USPTO, FDA Sued Over Angiomax Patent Extension
The Medicines Co. has hauled the U.S. Patent and Trademark Office, the Food and Drug Administration and the Department of Health and Human Services into court in an attempt to stretch...To view the full article, register now.
Already a subscriber? Click here to view full article